Opdivo Fallout: Rivalry In PD-1 Market To Continue, More Trials Could Mean More Failures

Opdivo's Phase III disappointment in first-line non-small cell lung cancer (NSCLC) is not the end of the world for Bristol-Myers Squibb, according to Datamonitor Healthcare analyst Dustin Phan. It also may not be the last surprise in a field with so many contenders and so many ongoing trials, as data from Pharmaprojects shows.